Differences in prenatal aneuploidy screening among African–American women with hemoglobin S variants

[1]  E. Vichinsky,et al.  Variability of homozygous sickle cell disease: The role of alpha and beta globin chain variation and other factors. , 2017, Blood cells, molecules & diseases.

[2]  Practice Bulletin No. 163 Summary: Screening for Fetal Aneuploidy , 2016, Obstetrics and gynecology.

[3]  D. Towner,et al.  Increased false positive Down syndrome screening in women with sickle cell anemia , 2015, Prenatal diagnosis.

[4]  P. Seed,et al.  Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. , 2015, Blood.

[5]  D. Towner,et al.  Obstetric, Perinatal, and Fetal Outcomes in Pregnancies With False-Positive Integrated Screening Results , 2014, Obstetrics and gynecology.

[6]  L. Dugoff.  First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. , 2010, Obstetrics and gynecology.

[7]  D. Barradas,et al.  Sickle cell disease and pregnancy outcomes: women of African descent. , 2010, American journal of preventive medicine.

[8]  V. Désilets,et al.  Obstetrical complications associated with abnormal maternal serum markers analytes. , 2008, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[9]  D. Rouse,et al.  Perinatal and Maternal Outcomes in Women With Sickle or Hemoglobin C Trait , 2007 .

[10]  A. Shrivastava,et al.  Study of placenta in sickle cell disorders. , 2007, Indian journal of pathology & microbiology.

[11]  M. Roudier,et al.  The placental-umbilical unit in sickle cell disease pregnancy: a model for studying in vivo functional adjustments to hypoxia in humans. , 2004, Human pathology.

[12]  S. Campbell,et al.  Placental morphogenesis in pregnancies with Down's syndrome might provide a clue to pre-eclampsia. , 2002, Placenta.

[13]  K. Spencer.  Age related detection and false positive rates when screening for Down's Syndrome in the first trimester using fetal nuchal translucency and maternal serum free βhCG and PAPP‐A , 2001, BJOG : an international journal of obstetrics and gynaecology.

[14]  J. Egan,et al.  Estimates for the sensitivity and false‐positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross‐identification and double‐positive results , 2001, Prenatal diagnosis.

[15]  M. Monga,et al.  Women with sickle cell trait are at increased risk for preeclampsia. , 1997, American journal of obstetrics and gynecology.

[16]  D. Towner,et al.  154: Obstetric, perinatal and fetal outcomes in pregnancies with positive integrated screening results , 2014 .

[17]  ACOG Practice Bulletin No. 78: hemoglobinopathies in pregnancy. , 2007, Obstetrics and gynecology.

[18]  J. Canick,et al.  A summary analysis of Down syndrome markers in the late first trimester. , 2007, Advances in clinical chemistry.

[19]  D. Sherer,et al.  Angiogenesis during implantation, and placental and early embryonic development. , 2001, Placenta.